In the pharmaceutical and biotech industry today the scope for and the breadth of stakeholders is expanding. Today’s development networks are emerging as consortiums that freely share learnings and experiences in order to make the best therapeutic development strategies. Yet, there is still more to do to identify and leverage our available knowledge networks. In this forum we will focus on strategies to best collaborate for novel therapeutic development.
Additionally this forum will also cover specific product investing. Unlike healthcare technology, most angel investors categorically dismiss medical product investing – especially for drug products. There are ways to bridge this gap through better preparation and understanding. In this forum we will also discuss common threads of deals angels invest in, the ones they don’t and how they make those decisions. Items such as the product, the team, deal structure, expected return, time to return, drugs vs. devices, regulatory strategy and life cycle management.
Learning Objective : 1) Learn the thinking of angel investors from a large angel investing syndicate.
2) Understand how to prepare your company for investor pitching
The Responsibility Industry, Agencies, and Early Education Own in Cure-Model Based Therapeutics
Dan Tierno, MA, MBA
Strategic Implementation Manager
Bayer, United States
What Angel Investors Think About Medical Product Investing
David Vulcano, MBA
Assistant Vice President and Responsible Executive for Clinical Research
Hospital Corporation of America (HCA), United States